MedTrace Logo

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

NCT01928485 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-10-22

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies how well green tea extract works in treating patients with low-risk prostate cancer. Green tea extract contains ingredients that may prevent or slow the growth of certain cancers.

Conditions

  • Stage I Prostate Cancer
  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer

Interventions

OTHER

active surveillance

Undergo active surveillance

DRUG

Sunphenon

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • Sanjay Gupta PhD

    lead OTHER

Principal Investigators

  • Lee Ponsky, MD · Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-30
Primary Completion
2016-10-05
Completion
2016-11-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928485 on ClinicalTrials.gov